Elasmogen Ltd is discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.
Elasmogen is progressing sight-saving therapies for inflammatory eye disease and in particular for those patients that have been let down by current small molecule and systemic monoclonal antibody therapies.
